| FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $511.57M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Aerovance |
Berkeley, Calif. |
5/4/06 |
$28 |
Aerovance received $28M in Series C funding and would get $32M more if certain milestonesare met; Clarus Ventures led the financing, which included Alta Partners and existing investorsApax Partners, Lehman Brothers, NGN Capital and Burrill & Co. |
Agile |
West Conshohocken, |
5/25/06 |
$12 |
The financing round was led by new investor ProQuest Investments and included existinginvestors Hillman Co., TL Ventures and PA Early Stage Partners |
Allostera |
Montreal |
5/18/06 |
C$2.1 ($1.9) |
The seed funding was provided by the Centre Quebecois de Valorisation des Biotechnologiesand Valorisation HSJ |
Asterion Ltd. |
Sheffield, UK |
5/12/06 |
£0.355 |
Biofusion plc led the financing round, which also included the White Rose Technology SeedcornFund; Biofusion owns 38% of Asterion |
Avidia Inc. |
Mountain View, Calif. |
5/9/06 |
$43.8 |
The Series C financing round was led by new investor Skyline Ventures and included HealthCare Ventures and existing investors Alloy Ventures, Amgen Ventures, MedImmune Ventures,Morgenthaler Ventures and TPG Ventures |
BioEnergy |
Norwell, Mass. |
5/16/06 |
$10 |
The company closed a $10M financing facility with Itera International Energy Corp. |
Cardiokine |
Philadelphia |
5/1/06 |
$50 |
Advent Venture Partners and Fidelity Biosciences led the Series B financing round, which includedTeachers Private Capital and Series A investors Perseus-Soros Biopharmaceutical Fund,HealthCare Ventures, Care Capital, CIBC Capital Partners and Burrill & Co. |
Cellca GmbH |
Laupheim, Germany |
5/24/06 |
€8.6 ($11) |
A regional consortium of banks, investors and national funders provided funding for the start- up company |
D-Pharm Ltd. |
Rehovot, Israel |
5/15/06 |
$10 |
The financing round was led by Clal Biotechnology Industries, Israel Healthcare Ventures and Pitango Venture Capital and included existing investors Care Capital, Gemini, Polar Communications and others |
FoldRx |
Cambridge, Mass. |
5/20/06 |
$43 |
Texas Pacific Group Ventures and Alta Partners led the Series B round, which included Novartis BioVenture Fund and original investors HealthCare Ventures and Fidelity Biosciences |
Intercept |
New York |
5/16/06 |
$41 |
The financing was led by Genextra SpA, with participation from Balyasny Asset Management and JAFCO Life Science Investment; Riverbank Capital Securities Inc. and Rodman & Renshaw LLC were co- placement agents |
KAI |
South San Francisco |
5/2/06 |
$35 |
The Series B financing was led by new investors Investor Growth Capital Inc. and Aberdare Ventures and included existing investors Skyline Ventures, InterWest Partners, Intersouth Partners, Delphi Ventures, Thomas Weisel Venture Partners and MDS Capital |
Kenta Biotech |
Berne, Switzerland |
5/8/06 |
CHF10 ($8.2) |
The company was spun out of Berna Biotech (a unit of Crucell NV), which has a stake of 36.7% in Kenta; management and four individual investors own the rest of the company |
Lux |
Jersey City, N.J. |
5/25/06 |
$36 |
The Series A financing round included equal participation from funds managed by HBM Partners AG, Novo A/S and SV Life Sciences |
MacroGenics |
Rockville, Md. |
5/17/06 |
$45 |
The Series C financing was led by Ventures West and included new investors Caisse de depot et placement du Quebec, RiverVest Venture Partners and Biogen Idec New Ventures and existing investors Texas Pacific Group Ventures, Alta Partners, InterWest Partners, MPM Capital, Mithra Ventures, OrbiMed Advisors and Red Abbey Venture Partners |
Midway |
Spring House, Pa. |
5/17/06 |
$0.5 |
The seed financing round was provided by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania |
Naryx Pharma |
Santa Barbara, Calif. |
5/22/06 |
$8 |
The Series B-2 financing round was led by Vivo Ventures and included Sutter Hill Ventures |
Onyvax Ltd. |
London |
5/8/06 |
£8 ($15.1) |
The Series C financing round was co-led by 3i and SR One and included investments from Barrie Haigh, Merlin Biosciences, MB Venture Capital Fund 1 NV, Alta Berkley Venture Partners and Alberville Ltd. |
Profectus |
Baltimore |
5/30/06 |
$3 |
Investors led by Cross Atlantic Capital Partners purchased $3M in Series A stock |
Protagen AG |
Dortmund, Germany |
5/8/06 |
€3.3 ($4.2) |
The MIG AG Funds 1 and 3 and S-Venture Capital Dortmund GmbH invested in the second-round financing |
Proteolix Inc. |
South San Francisco |
5/31/06 |
$45 |
The Series B financing was led by Delphi Ventures and included Series A investors U.S. Venture Partners, Advanced Technology Ventures, Latterell Venture Partners and The Vertical Group |
Qualyst Inc. |
Research Triangle Park, N.C. |
5/3/06 |
$5.5 |
The completed Series B round brought the total of the A and B rounds to $5.5M; Burton Advisers Ltd. was financial adviser |
U3 Pharma |
Munich, Germany |
5/22/06 |
€27 ($34.7) |
The Series C financing round was led by Life Sciences Partners, and included existing investors Alta Partners, Atlas Venture, E. de Rothschild Investment Partners and Bio*One Capital |
Viron |
London, Ontario |
5/16/06 |
$20 |
The Series A financing round was led by the Canadian Medical Discoveries Fund and included Amgen Ventures, BDC Venture Capital, GrowthWorks Capital and existing investors Novartis Pharma AG and Trudell Medical Ltd. |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
